BR112018010024A2 - compostos e composições úteis no tratamento de distúrbios relacionados a ntrk - Google Patents

compostos e composições úteis no tratamento de distúrbios relacionados a ntrk

Info

Publication number
BR112018010024A2
BR112018010024A2 BR112018010024A BR112018010024A BR112018010024A2 BR 112018010024 A2 BR112018010024 A2 BR 112018010024A2 BR 112018010024 A BR112018010024 A BR 112018010024A BR 112018010024 A BR112018010024 A BR 112018010024A BR 112018010024 A2 BR112018010024 A2 BR 112018010024A2
Authority
BR
Brazil
Prior art keywords
ntrk
compounds
treatment
related disorders
compositions useful
Prior art date
Application number
BR112018010024A
Other languages
English (en)
Other versions
BR112018010024A8 (pt
Inventor
V Miduturu Chandrasekhar
L Kim Joseph
Bifulco Neil Jr
Mark Wenglowsky Steven
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of BR112018010024A2 publication Critical patent/BR112018010024A2/pt
Publication of BR112018010024A8 publication Critical patent/BR112018010024A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção se refere a inibidores de ntrk que compreendem uma estrutura pirazolo[1,5-4]pirimidina-3-carbonitrila. eles são ativos contra ntrk de tipo selvagem e seus mutantes resistentes.
BR112018010024A 2015-11-19 2016-11-18 compostos e composições úteis no tratamento de distúrbios relacionados a ntrk BR112018010024A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257476P 2015-11-19 2015-11-19
PCT/US2016/062731 WO2017087778A1 (en) 2015-11-19 2016-11-18 Compounds and compositions useful for treating disorders related to ntrk

Publications (2)

Publication Number Publication Date
BR112018010024A2 true BR112018010024A2 (pt) 2018-11-21
BR112018010024A8 BR112018010024A8 (pt) 2019-02-26

Family

ID=57517997

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010024A BR112018010024A8 (pt) 2015-11-19 2016-11-18 compostos e composições úteis no tratamento de distúrbios relacionados a ntrk

Country Status (18)

Country Link
US (2) US10370379B2 (pt)
EP (1) EP3377497A1 (pt)
JP (1) JP2019500328A (pt)
KR (1) KR20180081790A (pt)
CN (1) CN108431008A (pt)
AR (1) AR106756A1 (pt)
AU (1) AU2016355196A1 (pt)
BR (1) BR112018010024A8 (pt)
CA (1) CA3005741A1 (pt)
HK (1) HK1259453A1 (pt)
IL (1) IL259164A (pt)
MX (1) MX2018006195A (pt)
PH (1) PH12018501065A1 (pt)
RU (1) RU2018122089A (pt)
SG (2) SG10201912607SA (pt)
TW (1) TWI733713B (pt)
WO (1) WO2017087778A1 (pt)
ZA (1) ZA201803530B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2916220T3 (es) 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
EP2970231A1 (en) 2013-03-15 2016-01-20 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
DK3057969T3 (en) 2013-10-17 2018-09-24 Blueprint Medicines Corp COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT
ES2924111T3 (es) 2013-10-25 2022-10-04 Blueprint Medicines Corp Inhibidores del receptor del factor de crecimiento de fibroblastos
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
EP3325481B1 (en) 2015-07-24 2019-06-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to kit and pdgfr
CN108137607B (zh) 2015-08-26 2021-04-06 缆图药品公司 适用于治疗与ntrk相关的病症的化合物和组合物
FI3371171T3 (fi) 2015-11-02 2024-01-10 Blueprint Medicines Corp Ret:n estäjiä
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
UY37155A (es) 2016-03-17 2017-10-31 Blueprint Medicines Corp Inhibidores de ret
CN109311889B (zh) 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
WO2019079649A1 (en) 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
US20210100795A1 (en) 2018-04-03 2021-04-08 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
PE20212196A1 (es) 2018-10-30 2021-11-16 Kronos Bio Inc Compuestos, composiciones, y metodos para modular la actividad cdk9
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
PT3856341T (pt) 2019-04-12 2023-12-12 Blueprint Medicines Corp Formas cristalinas de (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1- metil-1h-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4- il)piperazinil)pirimidin-5-il)etan-1-amina e métodos de preparação
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5251911A (en) 1992-12-09 1993-10-12 Blake Carlton E Safety construction for passenger vehicle
DE69732780T2 (de) 1996-10-02 2006-04-06 Novartis Ag Pyrimiderivate und verfahren zu ihrer herstellung
DE60332846D1 (de) 2002-09-04 2010-07-15 Pharmacopeia Llc Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
SG163576A1 (en) 2004-04-02 2010-08-30 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
RS57221B2 (sr) 2008-10-22 2020-08-31 Array Biopharma Inc Jedinjenja supstituisanog pirazolo[1,5-]pirimidina kao inhibitori trk kinaze
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AU2010352577A1 (en) 2010-05-05 2012-01-19 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as PKC-theta inhibitors
US8637516B2 (en) * 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
ES2916220T3 (es) 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
EP2890815B1 (en) 2012-08-31 2019-03-20 The Regents of the University of Colorado Methods for diagnosis and treatment of cancer
JP6457942B2 (ja) * 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
EP2914621B1 (en) * 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
WO2014118226A1 (en) 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
KR102148681B1 (ko) 2013-02-21 2020-08-27 칼리토르 사이언시즈, 엘엘씨 Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물
RU2015143517A (ru) * 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
EP2970231A1 (en) 2013-03-15 2016-01-20 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
DK3057969T3 (en) 2013-10-17 2018-09-24 Blueprint Medicines Corp COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT
ES2924111T3 (es) 2013-10-25 2022-10-04 Blueprint Medicines Corp Inhibidores del receptor del factor de crecimiento de fibroblastos
WO2015108328A1 (ko) * 2014-01-14 2015-07-23 주식회사 엘지생명과학 대장암 마커로서의 신규 ntrk1 융합유전자 및 이의 용도
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
JP6767875B2 (ja) * 2014-04-08 2020-10-14 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｔｇｆ−ベータ阻害剤としての２，３−二置換ピリジン化合物および使用方法
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
RU2708674C2 (ru) 2014-12-15 2019-12-11 СиЭмДжи ФАРМАСЬЮТИКАЛ КО., ЛТД. Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
US9981944B2 (en) 2015-02-20 2018-05-29 Rigel Pharmaceuticals, Inc GDF-8 inhibitors
EP3325481B1 (en) 2015-07-24 2019-06-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to kit and pdgfr
CN108137607B (zh) 2015-08-26 2021-04-06 缆图药品公司 适用于治疗与ntrk相关的病症的化合物和组合物
FI3371171T3 (fi) 2015-11-02 2024-01-10 Blueprint Medicines Corp Ret:n estäjiä
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
UY37155A (es) 2016-03-17 2017-10-31 Blueprint Medicines Corp Inhibidores de ret
CN109311889B (zh) 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
CN110022900A (zh) 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Also Published As

Publication number Publication date
AR106756A1 (es) 2018-02-14
US20170145018A1 (en) 2017-05-25
BR112018010024A8 (pt) 2019-02-26
HK1259453A1 (zh) 2019-11-29
IL259164A (en) 2018-06-28
AU2016355196A1 (en) 2018-06-21
US11059827B2 (en) 2021-07-13
US10370379B2 (en) 2019-08-06
CA3005741A1 (en) 2017-05-26
PH12018501065A1 (en) 2019-01-28
SG11201803920TA (en) 2018-06-28
RU2018122089A (ru) 2019-12-25
ZA201803530B (en) 2021-08-25
KR20180081790A (ko) 2018-07-17
JP2019500328A (ja) 2019-01-10
WO2017087778A1 (en) 2017-05-26
MX2018006195A (es) 2018-09-05
US20190382410A1 (en) 2019-12-19
TWI733713B (zh) 2021-07-21
CN108431008A (zh) 2018-08-21
RU2018122089A3 (pt) 2019-12-30
EP3377497A1 (en) 2018-09-26
TW201720826A (zh) 2017-06-16
SG10201912607SA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
BR112018010024A8 (pt) compostos e composições úteis no tratamento de distúrbios relacionados a ntrk
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
NZ631601A (en) Solid forms of a thiophosphoramidate nucleotide prodrug
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
BR112016006048A8 (pt) composições antimicrobianas
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX2016015762A (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor.
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
EP4292652A3 (en) Compounds for the treatment of glycogen storage disorders
SG10201804952QA (en) Glucosylceramide synthase inhibitors
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
MX2016008953A (es) Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas.
MX2017009929A (es) Composiciones y métodos para metabolismo muscular mejorado.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2697 DE 13/09/2022.